Skip to main content

Table 4 Study description, recruitment outcomes and three derived recruitment performance metrics for 8 observational studies

From: Early experience with an opt-in research register - Scottish Health Research Register (SHARE): a multi-method evaluation of participant recruitment performance

Study name Region(s) Involved Study Inclusion & Exclusion Criteria No. Requested by researchers No. Identified in EHRs No. Provided by SHARE to Research Team No. Recruited Percentage Identified and Recruited Percentage Provided and Recruited Percentage Fulfilled
Q West Inclusion:
• Age: 30–75
• Healthy
Exclusion:
• History of peptic ulcer disease
• History of Barrett’s oesophagus
• Previous H. pylori eradication
• Current use of PPIa/H2 blockers
• PPI use within last 12 months
• Upper GI cancer
• Pregnancy
150 1565 243 134 8.6 55.1 89.3
R East Inclusion:
• Aged 60–85
• Fluent in English
• Able to read
• Reliable study partner/informant
Exclusion:
• Dementia or any degenerative brain disorder
• Brain disease
• On cholinesterase inhibitors and/or memantine
• Receiving daily medications with the potential to affect cognition such as sedatives, pain medications, or anticonvulsants within 30 days
• Familial autosomal dominant Alzheimer’s disease or other familial dementing diseases
• Uncontrolled or untreated thyroid problems
• Clinically significant vitamin B12 or folic acid deficiency
• Chromosome21trisomy
• History within the past 2 years or current diagnosis of significant psychiatric illness
• History within the last 5 years of a serious infectious disease affecting the brain or head trauma resulting in protracted loss of consciousness
• Contraindications for MRI
• Major surgery, requiring general anaesthesia within 8 weeks or has not recovered
• Exposure to ionizing radiation
• Learning disability
• Currently participating in any interventional studies
• Currently participating in non-interventional study that involves exposure to radiation or neuropsychological testing
• History within the last 5 years of any type of cancer
• Currently on regular Vitamin B injections
• Currently taking anti-seizure medications
• Currently taking co-codamol or dihydrocodeine
• Currently taking opioids
• Currently taking benzodiazepines
• Stroke
• Blindness
• Deafness or significant hearing impairment
• Seizures
250 2365 700 91 3.8 13.0 36.4
S All Inclusion:
• Age: ≥16 years
• Diagnosis within the last 20 months of type 1diabetes or non-type 1 diabetes treated with diet non-type 1 diabetes on metformin monotherapy only
• Able to give informed consent
Exclusion:
• Non-type 1 diabetes on any oral hypoglycaemic agent other than metformin and who have had a prescription in the last 6 months
• Non-type 1 diabetes treated with an injectable therapy and who have had a prescription in the last 6 months
• Gestational diabetes
6000 3828 1040 246 6.4 23.7 4.1
T East Inclusion:
• Age: ≥70
• Heart Failure (NYHAb class II to IV)
• On frusemide) and ACE-ic
Exclusion:
• Living in nursing or residential home accommodation
30 99 36 19 19.2 52.8 63.3
U East Inclusion:
• Age: > 40
• COPD
Exclusion:
• Implemented during investigator screening
150 113 82 21 18.6 25.6 14.0
V West Inclusion:
• Age: 20–39
Exclusion:
• Insulin dependent diabetes
• Diseases of the Nervous System 1
• Diseases of the Nervous System 2
• Congenital malformations of the nervous system
• Inability to give informed consent
• Mental retardation
• Alzheimer’s Disease
• Other degenerative diseases of the CNSd, not elsewhere specified
• Other degenerative disorders of nervous system in diseases classified elsewhere
• myotonic dystrophy or other muscular dystrophy
• family history of myotonic dystrophy and never tested
• Severe concurrent medical condition, e.g. cardiac failure or respiratory failure
• Contraindications to MRIe
• History of major head trauma with loss of consciousness greater than a few minutes or with significant medical sequelae
8 66 10 7 10.6 70.0 87.5
W East Inclusion:
• Age: 40–85
• Type 2 Diabetes
• Blood pressure ≤ 140/80 mmHg
• HbA1ch value ≤64 mmol/mol
Exclusion:
• Blood pressure > 140/80 mmHg
• eGFRi < 60
• Atrial fibrillation
• Heart failure
• Peripheral vascular disease
• Stroke
• TIAj
• Ischaemic heart disease
• Inability to consent
30 238 24 5 2.1 20.8 16.7
X West Inclusion:
• Male or female ≥18 years of age
• Residing in Scotland
• Diagnosis of Bipolar Disorder
• At least three months lithium treatment in the past or current lithium treatment
190 16 6 6 37.5 100.0 3.2
Median (Interquartile) 150 (30–190) 238 (99–1565) 82 (24–243) 21 (7–91) 9.8 (6.4–18.6) 52.7 (23.7–55.1) 36.4 (14.0–63.3)
  1. aProton-pump inhibitor
  2. bthe New York Heart Association Functional Classification
  3. cangiotensin-converting-enzyme inhibitor
  4. dcentral nervous system
  5. emagnetic resonance imaging
  6. hHemoglobin A1c
  7. iestimated Glomerular Filtration Rate
  8. jTransient Ischaemic Attack